Merck CEO Belén Garijo Declares Strong Q3 2024 Growth, Reaffirms Path to Profitable 2024 Finish

Net sales up organically by 3.8% to € 5.3 billion EBITDA pre up organically by 16.9% to € 1.6 billion EBITDA ...

November 21, 2024 | Thursday | Company results
Jazz Pharmaceuticals Secures FDA Approval for Ziihera, First Dual HER2-Targeted Therapy for Advanced Biliary Tract Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zan...

November 21, 2024 | Thursday | News
AstraZeneca’s Tagrisso (osimertinib) Recommended for EU Approval in Unresectable EGFR-Mutated Lung Cancer

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with ...

November 19, 2024 | Tuesday | News
Tirzepatide Significantly Reduces Heart Failure Risk in Obese Patients with Preserved Ejection Fraction, New Data Show

Eli Lilly and Company (NYSE: LLY) announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of worsening ...

November 18, 2024 | Monday | News
MSD Acquires Global License for LM-299, a Novel PD-1/VEGF Bispecific Antibody from LaNova Medicines

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology ...

November 15, 2024 | Friday | News
TAE Life Sciences and Stella Pharma Announce Exclusive Collaboration to Expand BNCT Therapy in the U.S. and Europe

TAE Life Sciences (TLS), a leader in boron neutron capture therapy (BNCT) technology, and Stella Pharma, the pioneering developer of the boronophenylalan...

November 14, 2024 | Thursday | News
CEO Adam Levy Announces Record-Breaking Q3 Revenue for NEXGEL with 141% Year-Over-Year Growth to $2.94 Million

NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hyd...

November 14, 2024 | Thursday | Company results
Hexagon Health Sues Medtronic for Alleged Patent Infringement on Hernia Mesh Technology

The suit alleges Medtronic violated Hexagon Health's patents in developing and selling Dextile, a hernia mesh repair device.  Hexagon Health Inc. a...

November 14, 2024 | Thursday | News
Tirzepatide Reduces Type 2 Diabetes Risk by 94% in Three-Year SURMOUNT-1 Study, Lilly Reports

SURMOUNT-1 results show a 94% reduction in risk of progression to type 2 diabetes across all pooled doses of tirzepatide compared to placebo over three y...

November 14, 2024 | Thursday | News
Ontada and Datavant Forge Strategic Collaboration to Accelerate Oncology Innovation Through Real-World Data Integration

 Ontada®, a McKesson business and leader in community oncology real-world data, clinical education, and point of care technologies, has ...

November 13, 2024 | Wednesday | News
New Survey Reveals Critical Gaps in Care for Gynaecologic Cancer Patients, Highlighting Unmet Needs in Treatment Access and Support

GSK plc (LSE/NYSE: GSK) announced the results of a GSK-sponsored multinational survey designed to raise awareness of challenges that people with gynaecolog...

November 13, 2024 | Wednesday | News
Cardinal Health Expands Growth Strategy with Acquisition of Majority Stake in GI Alliance and Advanced Diabetes Supply Group

Acquisition of a majority stake in GI Alliance, the country's leading gastroenterology management services organization, to ac...

November 12, 2024 | Tuesday | News
IDEAYA Secures Global Rights to Biocytogen’s Innovative BsADC Candidate, IDE034

IDEAYA Secures Exclusive Global License for Biocytogen’s First-In-Class BsADC, B7H3/PTK7 Topo-I Payload (IDE034), Validating Biocytogen’s Ren...

November 12, 2024 | Tuesday | News
Stamford Health First in Connecticut to Offer AI-Powered Cardiovascular Screening Tool

Stamford Health's Heart & Vascular Institute has announced it will be the first in Connecticut to offer a new, AI-powered cardiovas...

November 12, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close